Accelerated development for Covid-19 monoclonal antibody
Drug Discovery World
JANUARY 3, 2023
A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery. . An accelerated development programme by AstraZeneca means a new Covid-19 product could be available in the second half of 2023, subject to trial readouts and regulatory reviews. .
Let's personalize your content